GlassScriptPhysician profile
Stacey E Elwood
NPI 1346682234
$5,904.57
in general payments reported to CMS, 2019-2025
22 companies · $2,549 in 2025
The $2,549 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $178 · 2023: $341 · 2024: $2,836 · 2025: $2,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,592 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,591.81 |
| Education | $134.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,637.21 | 2023-2025 | |
| Janssen Biotech, INC. | $1,412.71 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $950.21 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Lilly USA, LLC | $362.57 | 2024-2025 | Omvoh |
| Genzyme Corporation | $202.35 | 2023-2025 | |
| Qol Medical, LLC | $193.00 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $175.68 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $145.17 | 2023-2024 | Dificid, Zerbaxa, Recarbrio |
| Nestle Healthcare Nutrition INC. | $135.77 | 2022 | |
| Madrigal Pharmaceuticals | $105.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $97.25 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.98 | 2023-2024 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $81.46 | 2024-2025 | |
| Medtronic, INC. | $71.10 | 2023 | Interstim |
| Phathom Pharmaceuticals, INC. | $56.24 | 2024-2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $47.95 | 2024 | Stelara |
| Gilead Sciences, INC. | $43.53 | 2025 | |
| Dynavax Technologies Corporation | $30.69 | 2023-2024 | Heplisav-B |
| Azurity Pharmaceuticals, INC. | $22.92 | 2025 | Sutab |
| Aimmune Therapeutics, INC. | $21.38 | 2024 | |
| Ferring Pharmaceuticals INC. | $12.92 | 2023 | Rebyota |
| Echosens North America, INC. | $9.93 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Elwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.